Instrument template · DermatologyUpdated September 28, 2026

DLQI eCRF template with question 7 handled properly

The Dermatology Life Quality Index is the most used quality of life measure in skin disease trials. Ten questions, a one-week recall and a 0 to 30 score, including the one branching question most paper versions get wrong.

  • 10 questions, 6 domains
  • Branching on question 7
  • "Not relevant" stored separately

Free sandbox · No credit card · 21 CFR Part 11 aligned

Skin and daily life · Week 12

Over the last week:

Work or study (question 7)

YesNoNot relevant

Follow-up question shown because answer is No

How much of a problem at work or study?

A lotA littleNot at all
Skip logic mirrors the paper form

DLQI at a glance

  • Developed by Finlay and Khan and published in 1994. Ten questions on how skin disease affected the participant's life over the last week.
  • Each question scores 0 to 3, for a total of 0 to 30. Bands: 0 to 1 no effect, 2 to 5 small, 6 to 10 moderate, 11 to 20 very large, 21 to 30 extremely large effect.
  • Six domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment.
  • "Not relevant" answers score 0, and question 7 has a follow-up that only appears for some answers. Both need to be built correctly.
  • The DLQI is copyrighted; permission is required from the copyright holders (Cardiff University), and commercial use may involve a fee. A separate version (CDLQI) exists for children.

The instrument

Why dermatology trials default to the DLQI

Skin diseases such as psoriasis, atopic dermatitis and hidradenitis suppurativa rarely threaten life, but they disrupt it: itch that ruins sleep, clothing choices, work, relationships and the burden of treatment itself. The DLQI captures that impact in ten questions that take a couple of minutes, and it has been used in so many trials that its bands and change scores are widely understood by clinicians, payers and regulators.

In psoriasis and eczema trials it often appears as a key secondary endpoint alongside clinician-rated severity measures, with outcomes such as the proportion of participants reaching a DLQI of 0 or 1 (no effect on life). A change of about four points is commonly cited as the minimal clinically important difference.

The two rules that trip people up

First, several questions offer "not relevant". It scores 0, but it is not the same as "not at all", so store it as its own answer rather than recoding it at entry. Second, question 7 asks whether skin prevented work or study. "Yes" scores 3. "No" or "not relevant" leads to a follow-up on how much of a problem skin was at work or study, scored 2, 1 or 0. In Capture the follow-up is shown with skip logic only when it applies.

Missing answers

The developers' guidance is that one unanswered question is scored 0 and the total calculated, but two or more unanswered questions mean the DLQI is not scored. Making every question required on the ePRO form prevents most of this, and the rule belongs in your analysis plan.

DLQI total · Subject 005-0019

Week 12 total

4 / 30

Small
0-1 No effect2-5 Small6-10 Moderate11-20 Very large21-30 Extremely large
Baseline16
Week 49
Week 124

Structure

DLQI domains and questions

DomainQuestionsMax score
Symptoms and feelings1 to 26
Daily activities3 to 46
Leisure5 to 66
Work and school7 (with follow-up)3
Personal relationships8 to 96
Treatment103
Total10 questions30

Structure only. Obtain the DLQI, official translations and permission from the copyright holders before use.

Build it in Capture

Coded answers, the right branching, the licence on record

Each question is a single-choice item with its score stored as the code and the wording as the label, including a separate "not relevant" option. Skip logic shows the question 7 follow-up only for "No" or "not relevant". The licence number, holder and expiry sit on the form.

  • Single-choice questions with codes and labels in every export.
  • Skip logic for the question 7 follow-up.
  • All questions required, to avoid unscorable questionnaires.
  • Licence details recorded on the form, with collection blocked if it lapses.
PROMIS SF v1.0 · Fatigue 8a · Settings

Copyright & licence

Approval pending
Licence required

Licence number

Not recorded

Expiry date

Not recorded

Watermark shown to staff only. Participants never see it.

In a dermatology study

Patient-reported impact next to clinician scores

Dermatology trials pair the DLQI with clinician-rated severity scores recorded at the same visit. Capture keeps both in one casebook: the participant completes the DLQI on their phone before the visit, and the investigator records severity during it.

  • DLQI as ePRO, severity scores as site forms, on one schedule.
  • Visit windows keep the one-week recall aligned with the visit.
  • A daily itch diary between visits, if the protocol includes one.
EDC for dermatology trials
Schedule of assessments · Psoriasis study
AssessmentScrBLW2W4W8W12W16
DLQI (ePRO)
Severity score (site)
Itch NRS diaryDDDDDD
Vital signs

D = daily diary between visits

Test the question 7 branching yourself

Build the DLQI form in the sandbox and answer it on your phone.

Build your DLQI form free

As an endpoint

How dermatology trials report the DLQI

The DLQI is reported in two main ways. The first is mean change from baseline in the total score, often with the four-point minimal clinically important difference used to interpret it. The second is a responder outcome: the proportion of participants reaching DLQI 0 or 1, meaning their skin disease no longer has any effect on their life. In modern psoriasis trials, where clinician-rated clearance is often high, DLQI 0/1 has become one of the most persuasive outcomes for clinicians and payers.

Because the recall period is only one week, a single bad week around a visit can move the score. Keep visit windows tight, and schedule the DLQI before any in-clinic procedures on the day so that clinic experiences do not colour the answers.

Age and versions

The DLQI is for adults and adolescents from about 16 years. For children aged roughly 4 to 16, the Children's DLQI (CDLQI) has age-appropriate wording, and cartoon versions exist for younger children. Paediatric studies that span both age groups need both instruments and a rule for which one each participant completes.

Before go-live

DLQI setup checklist

Permission obtained

From the copyright holders; record licence details on the form.

Question 7 branching tested

Check every path: Yes, No and not relevant.

"Not relevant" kept distinct

Stored as its own answer, scored 0 in analysis.

All questions required

Two or more missing answers make the DLQI unscorable.

Age rule for CDLQI

Decide which instrument applies to adolescents in your study.

Responder outcome pre-specified

DLQI 0/1 and the MCID threshold named in the analysis plan.

FAQ

Questions about this template

Something not covered here? Ask us directly.

How is the DLQI scored?

Ten questions scored 0 to 3 are summed for a total of 0 to 30. Higher scores mean a larger effect on quality of life.

What do DLQI scores mean?

0 to 1 no effect, 2 to 5 small, 6 to 10 moderate, 11 to 20 very large and 21 to 30 extremely large effect on the patient's life.

How is "not relevant" scored?

As 0. Store it as its own answer rather than recoding it to "not at all" at entry.

How does question 7 work?

"Yes" (skin prevented work or study) scores 3. "No" or "not relevant" leads to a follow-up scored 2, 1 or 0. Capture shows the follow-up with skip logic.

What is the DLQI MCID?

A change of about four points is commonly cited as the minimal clinically important difference.

Is the DLQI free?

No. It is copyrighted and permission is required; commercial use may involve a fee.

Measure what skin disease does to daily life

Build the DLQI with correct branching and licence tracking. Free sandbox.

Build your DLQI form free